Compares sonrotoclax with venetoclax in adults with returned chronic lymphocytic leukemia
Tests sonrotoclax with antibody treatment in adults whose chronic lymphocytic leukemia has returned.
Plain-language title generated from the registry record
Registry title: A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Key facts
- Where
- Calgary, Edmonton, Montreal, Ottawa, Québec, St. John's, Toronto, Vancouver, and Winnipeg, CanadaSee the 9 sites
- Phase
- Phase 3
Where in Canada
- Arthur Je Child Comprehensive Cancer CentreCalgary, CanadaTaking people
- Cross Cancer InstituteEdmonton, CanadaTaking people
- Ciusss Nim HscmMontreal, CanadaTaking people
- The Ottawa HospitalOttawa, CanadaTaking people
- Chu de Quebec Universite Laval, Hopital de Lenfant Jesus, Centre Integre de Cancerologie (Cic)Québec, CanadaTaking people
- Newfoundland and Labrador Health ServicesSt. John's, CanadaTaking people
- Princess Margaret Cancer CentreToronto, CanadaTaking people
- British Columbia Cancer Agency the Vancouver CentreVancouver, CanadaTaking people
- CancerCare ManitobaWinnipeg, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- BeOne Medicines
- Trial code
- NCT06943872EU 2024-517131-52-00
- Record updated
- 23 October 2026
- Original description
The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The study will also compare how well sonrotoclax plus rituximab works versus venetoclax plus rituxumab in treating adults with R/R CLL/SLL. The safety of these treatments will also be assessed.Read full original descriptionShow less
A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The study will also compare how well sonrotoclax plus rituximab works versus venetoclax plus rituxumab in treating adults with R/R CLL/SLL. The safety of these treatments will also be assessed.
Inclusion: Confirmed diagnosis of CLL/SLL that meets the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria; Received one or more prior therapies for CLL/SLL. For each line of therapy, participants must have received at least 2 cycles of the therapy; Participants with prior BCL2i exposure are eligible if remission duration was ≥3 years with ≥2 years from last BCL2i intake; Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0, 1, or 2; Adequate organ function.
Exclusion: Prior autologous stem cell transplantation or chimeric antigen receptor T-cell therapy within 3 months before first dose of study drug; Prior allogeneic stem cell transplant with active graft-versus-host disease (GVHD), requiring immunosuppressive drugs for treatment of GVHD, or have taken calcineurin inhibitors within 4 weeks prior to consent; Severe or debilitating pulmonary disease; Clinically significant cardiovascular disease; NOTE: Other protocol defined Inclusion/Exclusion criteria may apply; Known active prolymphocytic leukemia or currently suspected Richter's transformation; Known central nervous system involvement by CLL/SLL.